Janus Henderson Group PLC lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 52.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,513,979 shares of the company’s stock after purchasing an additional 518,824 shares during the period. Janus Henderson Group PLC owned about 3.86% of Omnicell worth $79,408,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in Omnicell by 14.1% in the second quarter. BlackRock Inc. now owns 5,575,352 shares of the company’s stock worth $292,428,000 after acquiring an additional 690,464 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in Omnicell by 5.7% in the second quarter. Conestoga Capital Advisors LLC now owns 1,833,223 shares of the company’s stock worth $96,153,000 after acquiring an additional 98,515 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Omnicell by 1.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,538,878 shares of the company’s stock worth $66,787,000 after acquiring an additional 20,902 shares during the last quarter. Champlain Investment Partners LLC lifted its holdings in Omnicell by 3.2% in the first quarter. Champlain Investment Partners LLC now owns 1,505,445 shares of the company’s stock worth $65,336,000 after acquiring an additional 46,390 shares during the last quarter. Finally, Westwood Holdings Group Inc. lifted its holdings in Omnicell by 23.0% in the first quarter. Westwood Holdings Group Inc. now owns 650,078 shares of the company’s stock worth $28,213,000 after acquiring an additional 121,460 shares during the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.
OMCL has been the topic of a number of recent research reports. Piper Jaffray Companies raised their target price on shares of Omnicell from $44.00 to $55.00 and gave the stock a “neutral” rating in a report on Friday, July 27th. Benchmark initiated coverage on shares of Omnicell in a report on Friday, June 29th. They issued a “buy” rating and a $63.00 target price on the stock. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “sell” rating in a report on Thursday, August 2nd. Cantor Fitzgerald reissued a “buy” rating and issued a $63.00 target price on shares of Omnicell in a report on Thursday, July 26th. Finally, ValuEngine raised Omnicell from a “hold” rating to a “buy” rating in a report on Wednesday, June 20th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $53.80.
OMCL opened at $71.10 on Thursday. The company has a market cap of $2.70 billion, a PE ratio of 84.88, a price-to-earnings-growth ratio of 3.40 and a beta of 1.00. The company has a current ratio of 1.78, a quick ratio of 1.27 and a debt-to-equity ratio of 0.31. Omnicell, Inc. has a twelve month low of $39.75 and a twelve month high of $71.20.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, July 26th. The company reported $0.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.39 by $0.07. The company had revenue of $188.70 million for the quarter, compared to analysts’ expectations of $188.80 million. Omnicell had a return on equity of 5.88% and a net margin of 5.27%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.31 earnings per share. analysts anticipate that Omnicell, Inc. will post 1.35 earnings per share for the current year.
In other news, EVP Nhat H. Ngo sold 20,436 shares of Omnicell stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $55.00, for a total transaction of $1,123,980.00. Following the sale, the executive vice president now owns 57,750 shares of the company’s stock, valued at $3,176,250. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Peter J. Kuipers sold 2,818 shares of Omnicell stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $53.06, for a total value of $149,523.08. Following the sale, the insider now directly owns 54,370 shares in the company, valued at approximately $2,884,872.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 67,043 shares of company stock worth $3,799,860. Corporate insiders own 3.71% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Featured Story: How Do Tariffs Affect Trade Balances?
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.